LRRK2 and Parkinson disease: Additionally, since the majority of PD patients carrying the G2019S LRRK2 variant are heterozygous, a precision medicine approach of selectively reducing G2019S LRRK2 kinase activity while sparing wild-type LRRK2 physiological function could offer a potential safety advantage in this patient population.